Semin Plast Surg 2021; 35(03): 145-152
DOI: 10.1055/s-0041-1731461
Review Article

Current Advances in Hypertrophic Scar and Keloid Management

Natasha Barone
1   Faculty of Medicine and Health Sciences, McGill University, Montreal, Canada
,
Tyler Safran
2   Division of Plastic and Reconstructive Surgery, McGill University Health Centre, Montreal, Canada
,
Joshua Vorstenbosch
2   Division of Plastic and Reconstructive Surgery, McGill University Health Centre, Montreal, Canada
,
Peter G. Davison
2   Division of Plastic and Reconstructive Surgery, McGill University Health Centre, Montreal, Canada
,
Sabrina Cugno
2   Division of Plastic and Reconstructive Surgery, McGill University Health Centre, Montreal, Canada
,
Amanda M. Murphy
2   Division of Plastic and Reconstructive Surgery, McGill University Health Centre, Montreal, Canada
3   Division of Plastic and Reconstructive Surgery, Jewish General Hospital, Montreal, Canada
› Author Affiliations

Abstract

Hypertrophic scars and keloids are caused by excessive tissue response to dermal injury due to local fibroblast proliferation and collagen overproduction. This response occurs because of pathologic wound healing due to dysregulation in the inflammatory, proliferative, and/or remodeling phase. Patients with hypertrophic scars or keloids report reduced quality of life, physical status, and psychological health. Hypertrophic scars or keloids will develop in 30 to 90% of individuals, and despite their prevalence, treatment remains a challenge. Of the treatments currently available for hypertrophic scars and keloids few have been adequately supported by studies with appropriate experimental design. Here, we aim to review the available literature to provide up-to-date information on the etiology, epidemiology, histology, pathophysiology, prevention, and management options available for the treatment of hypertrophic scars and keloids and highlight areas where further research is required.



Publication History

Article published online:
15 July 2021

© 2021. Thieme. All rights reserved.

Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA

 
  • References

  • 1 Zhu Z, Ding J, Tredget EE. The molecular basis of hypertrophic scars. Burns Trauma 2016; 4: 2-2
  • 2 Bock O, Schmid-Ott G, Malewski P, Mrowietz U. Quality of life of patients with keloid and hypertrophic scarring. Arch Dermatol Res 2006; 297 (10) 433-438
  • 3 Lee HJ, Jang YJ. Recent understandings of biology, prophylaxis and treatment strategies for hypertrophic scars and keloids. Int J Mol Sci 2018; 19 (03) E711-E711
  • 4 Monstrey S, Middelkoop E, Vranckx JJ. et al. Updated scar management practical guidelines: non-invasive and invasive measures. J Plast Reconstr Aesthet Surg 2014; 67 (08) 1017-1025
  • 5 Baisch A, Riedel F. Hyperplastic scars and keloids. Part I: basics and prevention [in German]. HNO 2006; 54 (11) 893-904 , quiz 905
  • 6 Aarabi S, Longaker MT, Gurtner GC. Hypertrophic scar formation following burns and trauma: new approaches to treatment. PLoS Med 2007; 4 (09) e234-e234
  • 7 Arno AI, Gauglitz GG, Barret JP, Jeschke MG. Up-to-date approach to manage keloids and hypertrophic scars: a useful guide. Burns 2014; 40 (07) 1255-1266
  • 8 Berman B, Maderal A, Raphael B. Keloids and hypertrophic scars: pathophysiology, classification, and treatment. Dermatol Surg 2017; 43 (Suppl 1): S3-S18
  • 9 Mustoe TA, Cooter RD, Gold MH. et al; International Advisory Panel on Scar Management. International clinical recommendations on scar management. Plast Reconstr Surg 2002; 110 (02) 560-571
  • 10 Ghazawi FM, Zargham R, Gilardino MS, Sasseville D, Jafarian F. Insights into the pathophysiology of hypertrophic scars and keloids: how do they differ?. Adv Skin Wound Care 2018; 31 (01) 582-595
  • 11 Carswell L, Borger J. Hypertrophic Scarring Keloids. Treasure Island, FL: StatPearls; 2021
  • 12 Ojeh N, Bharatha A, Gaur U, Forde AL. Keloids: current and emerging therapies, Scars Burn Heal. 2020 6 ;2059513120940499
  • 13 McGinty S, Siddiqui WJ. Keloid. Treasure Island, FL: StatPearls; 2021
  • 14 Bayat A, Arscott G, Ollier WE, McGrouther DA, Ferguson MW. Keloid disease: clinical relevance of single versus multiple site scars. Br J Plast Surg 2005; 58 (01) 28-37
  • 15 Shih B, Bayat A. Genetics of keloid scarring. Arch Dermatol Res 2010; 302 (05) 319-339
  • 16 Burd A, Huang L. Hypertrophic response and keloid diathesis: two very different forms of scar. Plast Reconstr Surg 2005; 116 (07) 150e-157e
  • 17 Wolfram D, Tzankov A, Pülzl P, Piza-Katzer H. Hypertrophic scars and keloids--a review of their pathophysiology, risk factors, and therapeutic management. Dermatol Surg 2009; 35 (02) 171-181
  • 18 Robles DT, Berg D. Abnormal wound healing: keloids. Clin Dermatol 2007; 25 (01) 26-32
  • 19 Cosman B, Crikelair G, Ju D, Gaulin J, Lattes R. The surgical treatment of keloids. Plast Reconstr Surg 1961; 27 (04) 335-358
  • 20 Oluwasanmi JO. Keloids in the African. Clin Plast Surg 1974; 1 (01) 179-195
  • 21 Rockwell WB, Cohen IK, Ehrlich HP. Keloids and hypertrophic scars: a comprehensive review. Plast Reconstr Surg 1989; 84 (05) 827-837
  • 22 Sun LM, Wang KH, Lee YC. Keloid incidence in Asian people and its comorbidity with other fibrosis-related diseases: a nationwide population-based study. Arch Dermatol Res 2014; 306 (09) 803-808
  • 23 Bloom D. Heredity of keloids; review of the literature and report of a family with multiple keloids in five generations. N Y State J Med 1956; 56 (04) 511-519
  • 24 Seifert O, Mrowietz U. Keloid scarring: bench and bedside. Arch Dermatol Res 2009; 301 (04) 259-272
  • 25 Glass II DA. Current understanding of the genetic causes of keloid formation. J Investig Dermatol Symp Proc 2017; 18 (02) S50-S53
  • 26 Ramakrishnan KM, Thomas KP, Sundararajan CR. Study of 1,000 patients with keloids in South India. Plast Reconstr Surg 1974; 53 (03) 276-280
  • 27 Mouhari-Toure A, Saka B, Kombaté K. et al. Is there an association between keloids and blood groups?. ISRN Dermatol 2012; 2012: 750908-750908
  • 28 Marneros AG, Norris JE, Olsen BR, Reichenberger E. Clinical genetics of familial keloids. Arch Dermatol 2001; 137 (11) 1429-1434
  • 29 Goeminne L. A new probably X-linked inherited syndrome: congenital muscular torticollis, multiple keloids cryptorchidism and renal dysplasia. Acta Genet Med Gemellol (Roma) 1968; 17 (03) 439-467
  • 30 Omo-Dare P. Genetic studies on keloid. J Natl Med Assoc 1975; 67 (06) 428-432
  • 31 Gauglitz GG, Korting HC, Pavicic T, Ruzicka T, Jeschke MG. Hypertrophic scarring and keloids: pathomechanisms and current and emerging treatment strategies. Mol Med 2011; 17 (1-2): 113-125
  • 32 Schmieder SJ, Ferrer-Bruker SJ. Hypertrophic Scarring. Treasure Island, FL: StatPearls; 2021
  • 33 Finnerty CC, Jeschke MG, Branski LK, Barret JP, Dziewulski P, Herndon DN. Hypertrophic scarring: the greatest unmet challenge after burn injury. Lancet 2016; 388 (10052): 1427-1436
  • 34 Frangogiannis N. Transforming growth factor-β in tissue fibrosis, J Exp Med. 2020 217. 03; e20190103
  • 35 Ogawa R, Akita S, Akaishi S. et al. Diagnosis and treatment of keloids and hypertrophic scars-Japan Scar Workshop Consensus Document 2018. Burns Trauma 2019; 7: 39-39
  • 36 Naitoh M, Hosokawa N, Kubota H. et al. Upregulation of HSP47 and collagen type III in the dermal fibrotic disease, keloid. Biochem Biophys Res Commun 2001; 280 (05) 1316-1322
  • 37 Butler PD, Longaker MT, Yang GP. Current progress in keloid research and treatment. J Am Coll Surg 2008; 206 (04) 731-741
  • 38 Hunasgi S, Koneru A, Vanishree M, Shamala R. Keloid: a case report and review of pathophysiology and differences between keloid and hypertrophic scars. J Oral Maxillofac Pathol 2013; 17 (01) 116-120
  • 39 Halim AS, Emami A, Salahshourifar I, Kannan TP. Keloid scarring: understanding the genetic basis, advances, and prospects. Arch Plast Surg 2012; 39 (03) 184-189
  • 40 Rabello FB, Souza CD, Farina Júnior JA. Update on hypertrophic scar treatment. Clinics (São Paulo) 2014; 69 (08) 565-573
  • 41 Nast A, Eming S, Fluhr J. et al; German Society of Dermatology. German S2k guidelines for the therapy of pathological scars (hypertrophic scars and keloids). J Dtsch Dermatol Ges 2012; 10 (10) 747-762
  • 42 Son D, Harijan A. Overview of surgical scar prevention and management. J Korean Med Sci 2014; 29 (06) 751-757
  • 43 Bayat A, McGrouther DA, Ferguson MW. Skin scarring. BMJ 2003; 326 (7380): 88-92
  • 44 Wong VW, Akaishi S, Longaker MT, Gurtner GC. Pushing back: wound mechanotransduction in repair and regeneration. J Invest Dermatol 2011; 131 (11) 2186-2196
  • 45 Jiang Q, Chen J, Liu Z. Silicone gel sheeting for treating hypertrophic scars, Cochrane Database Syst Rev. 2019 2019. 06
  • 46 Hirshowitz B, Lindenbaum E, Har-Shai Y, Feitelberg L, Tendler M, Katz D. Static-electric field induction by a silicone cushion for the treatment of hypertrophic and keloid scars. Plast Reconstr Surg 1998; 101 (05) 1173-1183
  • 47 Eishi K, Bae SJ, Ogawa F, Hamasaki Y, Shimizu K, Katayama I. Silicone gel sheets relieve pain and pruritus with clinical improvement of keloid: possible target of mast cells. J Dermatolog Treat 2003; 14 (04) 248-252
  • 48 Reiffel RS. Prevention of hypertrophic scars by long-term paper tape application. Plast Reconstr Surg 1995; 96 (07) 1715-1718
  • 49 Tollefson TT, Kamangar F, Aminpour S, Lee A, Durbin-Johnson B, Tinling S. Comparison of effectiveness of silicone gel sheeting with microporous paper tape in the prevention of hypertrophic scarring in a rabbit model. Arch Facial Plast Surg 2012; 14 (01) 45-51
  • 50 Atkinson JA, McKenna KT, Barnett AG, McGrath DJ, Rudd M. A randomized, controlled trial to determine the efficacy of paper tape in preventing hypertrophic scar formation in surgical incisions that traverse Langer's skin tension lines. Plast Reconstr Surg 2005; 116 (06) 1648-1656 , discussion 1657–1658
  • 51 Commander SJ, Chamata E, Cox J, Dickey RM, Lee EI. Update on postsurgical scar management. Semin Plast Surg 2016; 30 (03) 122-128
  • 52 Lin Y-S, Ting P-S, Hsu K-C. Comparison of silicone sheets and paper tape for the management of postoperative scars: a randomized comparative study. Adv Skin Wound Care 2020; 33 (06) 1-6
  • 53 Poetschke J, Gauglitz GG. Onion extract. In: Téot L, Mustoe TA, Middelkoop E, Gauglitz GG. eds. Textbook on Scar Management: State of the Art Management and Emerging Technologies. Cham: Springer International Publishing; 2020: 209-213
  • 54 Phan TT, Lim IJ, Sun L. et al. Quercetin inhibits fibronectin production by keloid-derived fibroblasts. Implication for the treatment of excessive scars. J Dermatol Sci 2003; 33 (03) 192-194
  • 55 Beuth J, Hunzelmann N, Van Leendert R, Basten R, Noehle M, Schneider B. Safety and efficacy of local administration of contractubex to hypertrophic scars in comparison to corticosteroid treatment. Results of a multicenter, comparative epidemiological cohort study in Germany. In Vivo 2006; 20 (02) 277-283
  • 56 Chung VQ, Kelley L, Marra D, Jiang SB. Onion extract gel versus petrolatum emollient on new surgical scars: prospective double-blinded study. Dermatol Surg 2006; 32 (02) 193-197
  • 57 Jackson BA, Shelton AJ. Pilot study evaluating topical onion extract as treatment for postsurgical scars. Dermatol Surg 1999; 25 (04) 267-269
  • 58 Svensjö T, Pomahac B, Yao F, Slama J, Eriksson E. Accelerated healing of full-thickness skin wounds in a wet environment. Plast Reconstr Surg 2000; 106 (03) 602-612 , discussion 613–614
  • 59 Haedersdal M, Bech-Thomsen N, Poulsen T, Wulf HC. Ultraviolet exposure influences laser-induced wounds, scars, and hyperpigmentation: a murine study. Plast Reconstr Surg 1998; 101 (05) 1315-1322
  • 60 Due E, Rossen K, Sorensen LT, Kliem A, Karlsmark T, Haedersdal M. Effect of UV irradiation on cutaneous cicatrices: a randomized, controlled trial with clinical, skin reflectance, histological, immunohistochemical and biochemical evaluations. Acta Derm Venereol 2007; 87 (01) 27-32
  • 61 Gold MH, McGuire M, Mustoe TA. et al; International Advisory Panel on Scar Management. Updated international clinical recommendations on scar management: part 2--algorithms for scar prevention and treatment. Dermatol Surg 2014; 40 (08) 825-831
  • 62 Berman B, Kaufman J. Pilot study of the effect of postoperative imiquimod 5% cream on the recurrence rate of excised keloids. J Am Acad Dermatol 2002; 47 (4, Suppl): S209-S211
  • 63 Chuangsuwanich A, Gunjittisomram S. The efficacy of 5% imiquimod cream in the prevention of recurrence of excised keloids. J Med Assoc Thai 2007; 90 (07) 1363-1367
  • 64 Cação FM, Tanaka V, Messina MC. Failure of imiquimod 5% cream to prevent recurrence of surgically excised trunk keloids. Dermatol Surg 2009; 35 (04) 629-633
  • 65 Berman B, Harrison-Balestra C, Perez OA. et al. Treatment of keloid scars post-shave excision with imiquimod 5% cream: a prospective, double-blind, placebo-controlled pilot study. J Drugs Dermatol 2009; 8 (05) 455-458
  • 66 Bubna AK. Imiquimod - its role in the treatment of cutaneous malignancies. Indian J Pharmacol 2015; 47 (04) 354-359
  • 67 Verhiel S, Piatkowski de Grzymala A, van der Hulst R. Mechanism of action, efficacy, and adverse events of calcium antagonists in hypertrophic scars and keloids: a systematic review. Dermatol Surg 2015; 41 (12) 1343-1350
  • 68 Danielsen PL, Rea SM, Wood FM. et al. Verapamil is less effective than triamcinolone for prevention of keloid scar recurrence after excision in a randomized controlled trial. Acta Derm Venereol 2016; 96 (06) 774-778
  • 69 Margaret Shanthi FX, Ernest K, Dhanraj P. Comparison of intralesional verapamil with intralesional triamcinolone in the treatment of hypertrophic scars and keloids. Indian J Dermatol Venereol Leprol 2008; 74 (04) 343-348
  • 70 Atiyeh BS. Nonsurgical management of hypertrophic scars: evidence-based therapies, standard practices, and emerging methods. Aesthetic Plast Surg 2007; 31 (05) 468-492 , discussion 493–494
  • 71 Gholizadeh N, Sadrzadeh-Afshar M-S, Sheykhbahaei N. Intralesional corticosteroid injection as an effective treatment method for oral lesions: a meta-analysis. Braz J Pharm Sci 2020; •••: 56-56
  • 72 Boyadjiev C, Popchristova E, Mazgalova J. Histomorphologic changes in keloids treated with Kenacort. J Trauma 1995; 38 (02) 299-302
  • 73 Cruz NI, Korchin L. Inhibition of human keloid fibroblast growth by isotretinoin and triamcinolone acetonide in vitro. Ann Plast Surg 1994; 33 (04) 401-405
  • 74 Firooz A, Tehranchi-Nia Z, Ahmed AR. Benefits and risks of intralesional corticosteroid injection in the treatment of dermatological diseases. Clin Exp Dermatol 1995; 20 (05) 363-370
  • 75 Lumenta DB, Siepmann E, Kamolz LP. Internet-based survey on current practice for evaluation, prevention, and treatment of scars, hypertrophic scars, and keloids. Wound Repair Regen 2014; 22 (04) 483-491
  • 76 Juckett G, Hartman-Adams H. Management of keloids and hypertrophic scars. Am Fam Physician 2009; 80 (03) 253-260
  • 77 Bijlard E, Steltenpool S, Niessen FB. Intralesional 5-fluorouracil in keloid treatment: a systematic review. Acta Derm Venereol 2015; 95 (07) 778-782
  • 78 Ledon JA, Savas J, Franca K, Chacon A, Nouri K. Intralesional treatment for keloids and hypertrophic scars: a review. Dermatol Surg 2013; 39 (12) 1745-1757
  • 79 Jones CD, Guiot L, Samy M, Gorman M, Tehrani H. The use of chemotherapeutics for the treatment of keloid scars. Dermatol Rep 2015; 7 (02) 5880-5880
  • 80 Seo SH, Sung HW. Treatment of keloids and hypertrophic scars using topical and intralesional mitomycin C. J Eur Acad Dermatol Venereol 2012; 26 (05) 634-638
  • 81 Mandour Y, Bake H, Mofty E. et al. Topical versus interlesional mitomycin C in auricular keloids, Acta Otorrinolaringol Esp (Engl Ed). 2020 S0001-6519(20)30154-0
  • 82 Har-Shai Y, Amar M, Sabo E. Intralesional cryotherapy for enhancing the involution of hypertrophic scars and keloids. Plast Reconstr Surg 2003; 111 (06) 1841-1852
  • 83 Levy LL, Zeichner JA. Management of acne scarring, part II: a comparative review of non-laser-based, minimally invasive approaches. Am J Clin Dermatol 2012; 13 (05) 331-340
  • 84 O'Boyle CP, Shayan-Arani H, Hamada MW. Intralesional cryotherapy for hypertrophic scars and keloids: a review, Scars Burn Heal. 2017 3 ;2059513117702162
  • 85 van Leeuwen MC, Bulstra AE, Ket JC, Ritt MJ, van Leeuwen PA, Niessen FB. Intralesional cryotherapy for the treatment of keloid scars: evaluating effectiveness. Plast Reconstr Surg Glob Open 2015; 3 (06) e437-e437
  • 86 Zouboulis CC, Blume U, Büttner P, Orfanos CE. Outcomes of cryosurgery in keloids and hypertrophic scars. A prospective consecutive trial of case series. Arch Dermatol 1993; 129 (09) 1146-1151
  • 87 McGoldrick RB, Theodorakopoulou E, Azzopardi EA, Murison M. Lasers and ancillary treatments for scar management Part 2: keloid, hypertrophic, pigmented and acne scars, Scars Burn Heal. 2017 3 ;2059513116689805
  • 88 Litrowski N, Boullie MC, Dehesdin D, De Barros A, Joly P. Treatment of earlobe keloids by surgical excision and cryosurgery. J Eur Acad Dermatol Venereol 2014; 28 (10) 1324-1331
  • 89 Wilson AM. Eradication of keloids: surgical excision followed by a single injection of intralesional 5-fluorouracil and botulinum toxin. Can J Plast Surg 2013; 21 (02) 87-91
  • 90 Khan FA, Drucker NA, Larson SD, Taylor JA, Islam S. Pediatric earlobe keloids: outcomes and patterns of recurrence. J Pediatr Surg 2020; 55 (03) 461-464
  • 91 Lee SY, Park J. Postoperative electron beam radiotherapy for keloids: treatment outcome and factors associated with occurrence and recurrence. Ann Dermatol 2015; 27 (01) 53-58
  • 92 Oosterhoff TCH, Beekman VK, van der List JP, Niessen FB. Laser treatment of specific scar characteristics in hypertrophic scars and keloid: a systematic review. J Plast Reconstr Aesthet Surg 2021; 74 (01) 48-64
  • 93 Alster TS, Handrick C. Laser treatment of hypertrophic scars, keloids, and striae. Semin Cutan Med Surg 2000; 19 (04) 287-292
  • 94 Bhusari P, Shukla J, Kumar M. et al. Noninvasive treatment of keloid using customized Re-188 skin patch, Dermatol Ther (Heidelb). 2017; 30 (05)
  • 95 Mankowski P, Kanevsky J, Tomlinson J, Dyachenko A, Luc M. Optimizing radiotherapy for keloids: a meta-analysis systematic review comparing recurrence rates between different radiation modalities. Ann Plast Surg 2017; 78 (04) 403-411
  • 96 Ogawa R, Mitsuhashi K, Hyakusoku H, Miyashita T. Postoperative electron-beam irradiation therapy for keloids and hypertrophic scars: retrospective study of 147 cases followed for more than 18 months. Plast Reconstr Surg 2003; 111 (02) 547-553 , discussion 554–555
  • 97 Gassner HG, Sherris DA, Otley CC. Treatment of facial wounds with botulinum toxin A improves cosmetic outcome in primates. Plast Reconstr Surg 2000; 105 (06) 1948-1953 , discussion 1954–1955
  • 98 Zhibo X, Miaobo Z. Intralesional botulinum toxin type A injection as a new treatment measure for keloids. Plast Reconstr Surg 2009; 124 (05) 275e-277e
  • 99 Xiao Z, Zhang F, Cui Z. Treatment of hypertrophic scars with intralesional botulinum toxin type A injections: a preliminary report. Aesthetic Plast Surg 2009; 33 (03) 409-412
  • 100 Shaarawy E, Hegazy RA, Abdel Hay RM. Intralesional botulinum toxin type A equally effective and better tolerated than intralesional steroid in the treatment of keloids: a randomized controlled trial. J Cosmet Dermatol 2015; 14 (02) 161-166
  • 101 Zonari A, Martins TM, Paula AC. et al. Polyhydroxybutyrate-co-hydroxyvalerate structures loaded with adipose stem cells promote skin healing with reduced scarring. Acta Biomater 2015; 17: 170-181
  • 102 Bojanic C, To K, Hatoum A. et al. Mesenchymal stem cell therapy in hypertrophic and keloid scars. Cell Tissue Res 2021; 383 (03) 915-930
  • 103 Lee G, Hunter-Smith DJ, Rozen WM. Autologous fat grafting in keloids and hypertrophic scars: a review, Scars Burn Heal. 2017 3; 2059513117700157
  • 104 Williams EA, Thaller SR. The role of fat grafting in the treatment of keloid scars and venous ulcers. J Craniofac Surg 2019; 30 (03) 696-697
  • 105 Silva VZD, Albacete A, Horácio GS. et al. Evidences of autologous fat grafting for the treatment of keloids and hypertrophic scars. Rev Assoc Med Bras (1992) 2016; 62 (09) 862-866
  • 106 Pallua N, Baroncini A, Alharbi Z, Stromps JP. Improvement of facial scar appearance and microcirculation by autologous lipofilling. J Plast Reconstr Aesthet Surg 2014; 67 (08) 1033-1037
  • 107 Berman B, Flores F. Recurrence rates of excised keloids treated with postoperative triamcinolone acetonide injections or interferon alfa-2b injections. J Am Acad Dermatol 1997; 37 (5 Pt 1): 755-757
  • 108 al-Khawajah MM. Failure of interferon-alpha 2b in the treatment of mature keloids. Int J Dermatol 1996; 35 (07) 515-517
  • 109 Lee JH, Kim SE, Lee AY. Effects of interferon-alpha2b on keloid treatment with triamcinolone acetonide intralesional injection. Int J Dermatol 2008; 47 (02) 183-186
  • 110 Shah M, Foreman DM, Ferguson MW. Control of scarring in adult wounds by neutralising antibody to transforming growth factor beta. Lancet 1992; 339 (8787): 213-214
  • 111 McCormick LL, Zhang Y, Tootell E, Gilliam AC. Anti-TGF-beta treatment prevents skin and lung fibrosis in murine sclerodermatous graft-versus-host disease: a model for human scleroderma. J Immunol 1999; 163 (10) 5693-5699